UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 9월 2023 - 9:00PM
Business Wire
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated
to developing and commercializing innovative solutions that treat
urothelial and specialty cancers, today announced the grants of
inducement restricted stock units (“RSUs”) to 11 new employees, as
well as options (“Options”) to one of the new employees, in
connection with their employment with UroGen. These new team
members will support the ongoing commercial launch of Jelmyto®
(mitomycin) for pyelocalyceal solution, UroGen’s first approved
product, and the continued development of the Company’s
pipeline.
Up to 37,300 ordinary shares of UroGen are issuable upon the
vesting and settlement of the RSUs and up to 30,000 ordinary shares
are issuable upon the vesting and exercise of the Options. The
Options have an exercise price of $17.94 per share, which was the
closing price of the ordinary shares on September 6, 2023, the date
of grant, as reported on The Nasdaq Stock Market. The RSUs and
Options will vest equally over three years, with one-third of the
underlying shares vesting each year on the anniversary of the
vesting date, subject in each case to the employee’s continued
service relationship with UroGen.
The RSUs and Options are subject to the terms and conditions of
UroGen’s 2019 Inducement Plan and RSU and Option grant notice and
agreements thereunder. The RSUs and Options were granted as an
inducement material to each employee entering into employment with
UroGen in accordance with Nasdaq listing Rule 5635(c)(4).
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and
commercializing innovative solutions that treat urothelial and
specialty cancers because patients deserve better options. UroGen
has developed RTGel® reverse-thermal hydrogel, a proprietary
sustained release, hydrogel-based platform technology that has the
potential to improve therapeutic profiles of existing drugs.
UroGen’s sustained release technology is designed to enable longer
exposure of the urinary tract tissue to medications, making local
therapy a potentially more effective treatment option. UroGen’s
first commercial product Jelmyto® (mitomycin) for pyelocalyceal
solution, and investigational treatment UGN-102 (mitomycin) for
intravesical solution for patients with low-grade non-muscle
invasive bladder cancer, are designed to ablate tumors by
non-surgical means. UroGen is headquartered in Princeton, New
Jersey with operations in Israel. Visit www.urogen.com to learn
more or follow us on Twitter, @UroGenPharma.
Jelmyto®, RTGel® and UroGen® are registered trademarks of UroGen
Pharma Ltd.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230908931196/en/
INVESTOR CONTACT: Vincent Perrone
vincent.perrone@urogen.com (609) 460-3588 MEDIA CONTACT: Cindy
Romano Cindy.romano@urogen.com (609) 460-3583
UroGen Pharma (NASDAQ:URGN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
UroGen Pharma (NASDAQ:URGN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024